Essay On Hepatitis C Mono

Require BOTH FibroTest > 0.59 AND Fibroscan > 9.5kPa. (The AASLD/IDSA HCV guidance panel notes that the

Many people don’t understand how dangerous Hepatitis C is because it is not commonly known about as much as Hepatitis A or B. This disease is however very serious. Although frequently asymptomatic in time the virus can lead to cirrhosis, liver cancer and liver failure. Symptoms of HCV are jaundice (yellowing of the eyes), stomach pain, nausea and fatigue. Treatment options for the disease, if caught early enough is a combination of medications or depending on the degree of damage, a liver transplant. ”For some people, hepatitis C is a short-term illness but for 70%-85% of people who become infected with

This case study is about Abdul Chidiac, a 51 year old male, married with 4 children. He had a medical history of hypertension, hypercholesterolaemia and cirrhosis with two admissions in the last six months. He is a smoker and drinks beer, 5-6 bottles per day. As Carithers & McClain (2010) explained the patient’s medical history is another indicator of the risk for cirrhosis; the progression to cirrhosis is adaptable and may take time over weeks or many years. Cirrhosis is a liver disease characterized by permanent scarring of the

Hepatitis C is an inflammation of the liver's cells and tissues caused by the hepatitis C virus (HCV).

The strain of genotypes is not differentiated by the severity of the disease. However, there will make a distinction in the regimen and the duration of the treatment (CDC, 2016). Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD). The criteria of who should receive the treatment include how much the virus in the body, the strain of hepatitis C, the degree of liver inflammation or damage, comorbidity, and response to previous treatment (Infectious Diseases Society of America [IDSA], 2016). The highest priority for treatment should give to a patient with advanced fibrosis and compensated cirrhosis (IDSA, 2016). Moreover, treatment priority should provide to the patient who has a high risk of transmitting the disease from and to others, such as individuals who are active injection drug users and hemodialysis patients (IDSA, 2016).

Additionally, many chronic liver diseases can lead to cirrhosis. For example, nonalcoholic fatty liver disease (NAFLD) can lead to cirrhosis and is associated with obesity, hyperlipidemia, metabolic syndrome and type 2 diabetes mellitus. Hereditary metabolic disorders such as hemochromatosis and Wilson disease can also lead to cirrhosis (McCance & Heuther, 2014). It seems the cause of cirrhosis is multifaceted. Additionally, many diseases can lead to cirrhosis and it is understandable why the etiology of cirrhosis has not been parsed out, especially because the cause can differ from a

If someone is getting tested for Hepatitis C, they will first take an antibody test. This test will detect if antibodies are present in the blood, which will tell if the person has ever had Hepatitis C, not if they currently possess it (“Who Should”). If the antibody test comes back positive, a qualitative test will then be run. This test declares tells if someone is currently infected with Hepatitis C. A quantitative test can also be run, which shows the amount of Hepatitis C that is in the blood (“Who Should”). There are two main medications that are used to treat Hepatitis C. The first being Pegylated Interferon and another being Ribavirin. Both medications are used for the treatment of adult patients with chronic liver disease (FDA). These medications are used in place of the vaccine that has not been created for Hepatitis C. Therefore, Hepatitis C can be detected easily and is treatable.

There are a number of individuals who may be suffering from an illness and not even be aware they have an illness. One example of such illness is Hepatitis C (HCV). Hepatitis C is a severe disease of the liver. It is caused by the Hepatitis C virus (Centers for Disease Control and Prevention (CDC), 2015). As a result, Hepatitis C has been termed a silent epidemic (CDC, 2015). This is because a lot of individuals have Hepatitis C and don’t even realize they have the infection (CDC, 2015). As the infection begins to progress over time, it could cause acute issues to the liver (CDC, 2015). Those issues could be things like damage to the liver, the liver could fail to function, cirrhosis, or even cancer of the liver (CDC, 2015). However, screening for Hepatitis C will allow an individual to benefit from treatments that are available, hence eliminating the disease from the body and preventing the liver from undergoing any further damage (CDC, 2015).

Hepatitis C virus (HCV) infection causes chronic liver. Over time, infections can lead to liver damage, liver cancer, and even liver failure.

Chronic hepatitis C virus (HCV) causes inflammation of the liver, eventually leading to tissue damage. Cirrhosis is the result of extensive scarring of the liver. The Centers for Disease Control and Prevention state that HCV typically causes cirrhosis in 5 to 20 percent of infected people over a period of 20 to 30 years. Overall, cirrhosis develops 20 to 30 percent of the time. Progression to cirrhosis may be accelerated in people who are older, obese, drink alcohol, or are immune-suppressed (such as people who are coinfected with HIV).

Hepatitis C is a liver disease caused by the Hepatitis C virus. The disease can be either acute or a chronic infection, which can be mild or a lifelong disease. This disease also is the major cause of cirrhosis and liver cancer. The disease is slow moving and sometimes take up to thirty years to damage the liver. In the United States there are an estimated three to four million people with the disease and are not even aware. Approximately thirty percent of the individuals infected within six months have no symptoms and will not even be aware that they have the disease. In the remaining seventy percent infected the disease will become chronic. According to statics one hundred and seventy million people are chronically infected worldwide.

Hepatic fibrosis is a dynamic scarring process in which chronic inflammation stimulates production and accumulation of collagen and extracellular matrix proteins. The hepatic stellate cells are the primary cells responsible for producing these extracellular matrix proteins. Over time patients with chronic hepatitis C infection experience an increase in the total collagen content, which contributes to the development of liver fibrosis, with the potential to progress to cirrhosis. This dynamic process also involves remodelling and regression of the fibrous tissue via breakdown of the matrix proteins by the protease enzymes matrix metalloproteinases (MMP). Balance of the remodelling

The leading cause of liver damage due to viral hepatitis B virus and hepatitis C virus represents a major health problem in the United States. “CDC estimates that approximately 3.2 million of Americans are chronically infected with hepatitis C virus, with an estimate of 8,000 to 10,000 hepatitis C virus related deaths annually” (CDC foundation).

Hepatocellular carcinoma is one of the most common cause of cancer death globally. The epidemiology varies regionally. This variation could be due to the difference in aetiologies. Among all the risk factors hepatitis B and C infections are the most important risk factors of hepatocellular carcinoma. Hepatocellular carcinoma rates are higher in developing countries and so is the incidence of hepatitis B and hepatitis C. However the figures in the developed countries are contrary. This could be due to the better hepatitis B virus vaccination programs, better food hygiene, and better control of the transfusion related mechanisms. In Pakistan

Hepatitis C is an inflammation of the liver’s cells and tissues caused by the hepatitis C virus (HCV).